Latest News Archive

Please select Category, Year, and then Month to display items

A ‘vertical theological perspective’ on Old Testament books

21 December 2020 | Story Eugene Seegers | Photo Sonia Small

Prof Snyman_web read more — Prof Fanie Snyman, retired Dean of the Faculty of Theology and Religion, is the first South African to publish a volume in the respected Tyndale Old Testament Commentaries series, which deals with the Bible books of Nahum, Habakkuk, and Zephaniah.

Against the backdrop of the Faculty of Theology and Religion’s 40th anniversary, Prof Fanie Snyman, retired Dean and research associate, has recently published a commentary in the Tyndale Old Testament Commentaries series based in Cambridge, England, on the prophetic books Nahum, Habakkuk, and Zephaniah of the Old Testament. What makes his book special is that Prof Snyman is the first and for the foreseeable future the only South African Old Testament scholar to be commissioned to publish in this distinguished commentary series. This commentary series is widely read and consulted in the English-speaking scholarly communities of Africa, Australia, Great Britain, New Zealand, the USA, and many European countries.

In a virtual ‘sit-down’ with Prof Fanie, he explained how a research volume of this type is usually compiled: It starts with a verse-by-verse analysis of the Bible books, looking at the literary aspects of how the passage was written as well as considering its historical, social, and cultural background. This is done to obtain a better overall understanding of the text. Secondly, a volume of commentary is not merely regurgitating knowledge that has already been generated. Prof Fanie says that “it must deliver new, fresh perspectives on the current state of research on these books. What can I contribute to the understanding of these writings?” To accomplish this, he had to pore over stacks of research on these prophetic works to be as current as possible with modern research.

First contributor from Africa

Dr David Firth, the series editor, says: “Over the nearly sixty-year history of the Tyndale Old Testament Commentaries, we have not previously had any contributors from Africa. That has now been put right with the release of Prof SD Snyman’s new volume on Nahum, Habakkuk, and Zephaniah. Prof Snyman has brought together his expertise on the prophetic literature of the Old Testament and theological awareness to present a fresh work on these often-neglected books. Through his careful attention to how these books functioned in their ancient setting and mastery of the secondary literature, he is also able to point to the enduring importance of each of these books for contemporary readers. As such, he has admirably fulfilled the brief for the series and produced a volume that will serve a new generation who come to these books.”

Prof Fanie affirms that the burning issues raised in each of these books regarding situations in ancient Israel often mimic comparable issues in our modern society. For example, he underscores how Nahum brings the misuse of political power to the fore, a current and topical point of contention. Prof Snyman says: “My aim was to create a vertical theological perspective of that historical situation against the backdrop of contemporary issues. I believe that these texts have a relevance for us and upon us today.”

Other international works

This book is the third one published internationally by Prof Snyman. In 2012, he published a book on the prophetic literature of the Old Testament together with a Dutch colleague in the USA. In 2015, he published a commentary on the book of Malachi in Europe. This book was awarded the UFS Book Prize for Distinguished Scholarship in 2017.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept